Roche Forms New Clinical Research Hub In Singapore To Accelerate Progress In Personalized Medicine
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Roche announced Jan. 28 a major strategic alliance with Singapore's leading scientific and medical institutions to establish a new translational research hub in Singapore
You may also be interested in...
Singapore Gains Momentum As Major R&D, Manufacturing Hub; Sees Double-digit Pharma Sector Growth
SHANGHAI - Output of Singapore's biomedical manufacturing cluster increased 14.8 percent last year, according to Singapore's Economic Development Board. Within the cluster, the pharmaceuticals segment grew 15.6 percent with higher levels of production of active pharmaceutical ingredients. Output of the medical technology segment edged up 0.8 percent to meet export orders for surgical and medical instruments
Singapore Gains Momentum As Major R&D, Manufacturing Hub; Sees Double-digit Pharma Sector Growth
SHANGHAI - Output of Singapore's biomedical manufacturing cluster increased 14.8 percent last year, according to Singapore's Economic Development Board. Within the cluster, the pharmaceuticals segment grew 15.6 percent with higher levels of production of active pharmaceutical ingredients. Output of the medical technology segment edged up 0.8 percent to meet export orders for surgical and medical instruments
Investing In China: Views From Windhover's PharmAsia Summit
It's common wisdom within the halls of Big Pharma to look East--especially to China--for future revenue growth as increasing regulatory oversight and reimbursement hurdles in the U.S. and Europe create commercial challenges